Education
About Us
Working with TipRanks
Follow Us
Aardvark Therapeutics, Inc. (AARD)
NASDAQ:AARD
AARD Stock Chart & Stats
$4.90
--
Market closed
$4.90
--
Day’s Range― - ―
52-Week Range$4.74 - $17.94
Previous CloseN/A
VolumeN/A
Average Volume (3M)166.37K
Market Cap
$122.80M
Enterprise Value$84.39M
Total Cash (Recent Filing)$126.35M
Total Debt (Recent Filing)$545.00K
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Apr 06, 2026EPS Estimate
-0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.75
Shares Outstanding21,773,272
10 Day Avg. Volume148,283
30 Day Avg. Volume166,372
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)-3.38
Price to Sales (P/S)0.00
P/FCF Ratio-10.15
Enterprise Value/Market Cap0.69
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-8.44K
Enterprise Value/Ebitda-1.62
Forecast
1Y Price Target
$18.88Price Target Upside285.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.79
Revenue Forecast (FY)$300.00K
Bulls Say, Bears Say
Bulls Say
Dose-dependent Safety ProfileCardiac observations were reversible and occurred only at doses above planned therapeutic levels and were not seen in other trials at intended doses, supporting a manageable safety profile at target dosing.
Pipeline Financing And Resource AllocationA newly formed Ardia subsidiary will independently finance development of a topical TAS2R program, reducing the parent company's need to fund that program and preserving resources for core assets.
Regulatory EngagementFDA has not placed the HERO study on clinical hold and the company plans to consult with the agency to clarify the path forward, which could preserve regulatory options and keep the approval pathway viable.
Bears Say
Analyst Sentiment And Funding UncertaintyAnalyst downgrades and suspended price targets reflect increased uncertainty, and unclear timelines combined with limited financial runway raise questions about the company's ability to advance the program without additional funding.
Clinical Pause And Milestone RiskVoluntary pause of the Phase 3 HERO study after cardiac observations will delay availability of pivotal topline results and undermines near-term clinical milestones.
Mechanism-based Cardiac RiskThe drug's target is expressed in heart tissue and may affect cardiac function, raising the possibility of mechanism-based safety concerns, particularly given the target patient population's high rate of cardiovascular comorbidities.
Aardvark Therapeutics, Inc. News
AARD FAQ
What was Aardvark Therapeutics, Inc.’s price range in the past 12 months?
Aardvark Therapeutics, Inc. lowest stock price was $4.74 and its highest was $17.94 in the past 12 months.
What is Aardvark Therapeutics, Inc.’s market cap?
Aardvark Therapeutics, Inc.’s market cap is $122.80M.
When is Aardvark Therapeutics, Inc.’s upcoming earnings report date?
Aardvark Therapeutics, Inc.’s upcoming earnings report date is Apr 06, 2026 which is in 31 days.
How were Aardvark Therapeutics, Inc.’s earnings last quarter?
Aardvark Therapeutics, Inc. released its earnings results on Nov 13, 2025. The company reported -$0.75 earnings per share for the quarter, beating the consensus estimate of -$0.799 by $0.049.
Is Aardvark Therapeutics, Inc. overvalued?
According to Wall Street analysts Aardvark Therapeutics, Inc.’s price is currently Undervalued.
Does Aardvark Therapeutics, Inc. pay dividends?
Aardvark Therapeutics, Inc. does not currently pay dividends.
What is Aardvark Therapeutics, Inc.’s EPS estimate?
Aardvark Therapeutics, Inc.’s EPS estimate is -0.83.
How many shares outstanding does Aardvark Therapeutics, Inc. have?
Aardvark Therapeutics, Inc. has 21,773,272 shares outstanding.
What happened to Aardvark Therapeutics, Inc.’s price movement after its last earnings report?
Aardvark Therapeutics, Inc. reported an EPS of -$0.75 in its last earnings report, beating expectations of -$0.799. Following the earnings report the stock price went down -8.656%.
Which hedge fund is a major shareholder of Aardvark Therapeutics, Inc.?
Currently, no hedge funds are holding shares in AARD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aardvark Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.88 (285.31% Upside)
$18.88 (285.31% Upside)
Insider Transactions
Bought Shares
Worth $144.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 6.6%
Last 30 Days ▼ 6.6%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Fundamentals
Return on Equity
-48.06%
Trailing 12-Months
Asset Growth
59.10%
Trailing 12-Months
Company Description
Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.
AARD Stock 12 Month Forecast
Average Price Target
$18.88
▲(285.31% Upside)
Technical Analysis
Ownership Overview
42.42% Insiders
3.38% Mutual Funds
27.09% Other Institutional Investors
21.23% Public Companies and
Individual Investors